“Safety and Target Engagement of Anti-Interleukin-33 Antibody Tozorakimab in Healthy Adults and COPD Patients: A Phase 1 Study”

https://pubmed.ncbi.nlm.nih.gov/38115209

This phase 1 study found that the anti-interleukin-33 antibody tozorakimab was safe, well-tolerated, and demonstrated target engagement in healthy adults and patients with chronic obstructive pulmonary disease, supporting its further clinical development.